Jennalee Beazley

Jennalee Beazley is an Associate at Williams & Connolly LLP, focusing her practice on patent litigation, particularly within the pharmaceutical and life sciences sectors. Her work primarily involves representing plaintiff operating companies in complex Biologics Price Competition and Innovation Act (BPCIA) disputes, as evidenced by her consistent appearances on behalf of Regeneron Pharmaceuticals, Inc.

Ms. Beazley has played a role in significant patent infringement cases defending Regeneron's Eylea® (aflibercept) against biosimilar manufacturers. She was Counsel or Lead Counsel in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al., which involved 24 asserted patents and saw Regeneron secure a permanent injunction in June 2024 before eventually reaching a settlement in April 2025. Similarly, in Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., she was Lead Counsel, a case where the Federal Circuit affirmed a preliminary injunction against Celltrion in March 2025, leading to a settlement in October 2025. She also served as lead counsel in Regeneron Pharmaceuticals, Inc. v. Sandoz Inc., which settled in September 2025. These settlements typically permit the biosimilar products to launch in the U.S. market by late 2026. While some of the defendants in these cases have filed petitions for inter partes review (IPR) against Regeneron's patents at the USPTO, her direct appearance in PTAB proceedings is not explicitly documented.

Ms. Beazley earned her J.D., cum laude, from Duke University School of Law in 2022, where she was Editor-in-Chief of the Duke Law Journal. She completed her undergraduate studies at Virginia Tech, receiving a B.A., summa cum laude, in 2019. She is admitted to practice in Pennsylvania and the District of Columbia.